DDInter416 DDInter1094
This drug is a broad spectrum antimycotic or antifungal agent. Clotrimazole's antimycotic properties were discovered in the late 1960s. Clotrimazole falls under the _imidazole_ category of _azole_ antifungals, possessing broad-spectrum antimycotic activity. It is available in various preparations, including creams, pessaries, and troche formulations (slowly dissolving tablets). As well as its antifungal activity, clotrimazole has become a drug of interest in treating several other diseases such as sickle cell disease, malaria and some cancers. The minimal side effect profile of this drug and its uncomplicated metabolic profile have led it to gain widespread acceptance for the treatment of mycotic outbreaks such as vaginal yeast infections as well as athlete's foot.
Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC.
Clotrimazole {u} (Compound) resembles {v} (Compound) Darifenacin
Darifenacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Clotrimazole {u} (Compound) resembles {v} (Compound) Methadone
Methadone {u} may lead to a major life threatening interaction when taken with {v} Lorlatinib
Clotrimazole {u} (Compound) resembles {v} (Compound) Darifenacin
Darifenacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bexarotene
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lorlatinib
Clotrimazole {u} (Compound) resembles {v} (Compound) Diphenidol
Diphenidol {u} (Compound) resembles {v} (Compound) Levacetylmethadol
Levacetylmethadol {u} may lead to a major life threatening interaction when taken with {v} Lorlatinib
Clotrimazole {u} (Compound) resembles {v} (Compound) Methadone
Methadone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bexarotene
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lorlatinib
Clotrimazole {u} (Compound) resembles {v} (Compound) Darifenacin
Darifenacin {u} may lead to a major life threatening interaction when taken with {v} Tamoxifen
Tamoxifen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Clotrimazole {u} (Compound) resembles {v} (Compound) Diphenoxylate
Diphenoxylate {u} (Compound) resembles {v} (Compound) Methadone
Methadone {u} may lead to a major life threatening interaction when taken with {v} Lorlatinib
Clotrimazole {u} (Compound) resembles {v} (Compound) Diphenidol
Diphenidol {u} (Compound) resembles {v} (Compound) Fexofenadine
Fexofenadine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Clotrimazole {u} (Compound) resembles {v} (Compound) Methadone
Methadone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Tofacitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Clotrimazole {u} (Compound) resembles {v} (Compound) Darifenacin
Darifenacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Halofantrine
Halofantrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Clotrimazole (Compound) resembles Darifenacin (Compound) and Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Clotrimazole (Compound) resembles Methadone (Compound) and Methadone may lead to a major life threatening interaction when taken with Lorlatinib
Clotrimazole (Compound) resembles Darifenacin (Compound) and Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Clotrimazole (Compound) resembles Diphenidol (Compound) and Diphenidol (Compound) resembles Levacetylmethadol (Compound) and Levacetylmethadol may lead to a major life threatening interaction when taken with Lorlatinib
Clotrimazole (Compound) resembles Methadone (Compound) and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Clotrimazole (Compound) resembles Darifenacin (Compound) and Darifenacin may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Clotrimazole (Compound) resembles Diphenoxylate (Compound) and Diphenoxylate (Compound) resembles Methadone (Compound) and Methadone may lead to a major life threatening interaction when taken with Lorlatinib
Clotrimazole (Compound) resembles Diphenidol (Compound) and Diphenidol (Compound) resembles Fexofenadine (Compound) and Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Clotrimazole (Compound) resembles Methadone (Compound) and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Clotrimazole (Compound) resembles Darifenacin (Compound) and Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Halofantrine and Halofantrine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib